Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA159723
Max Phase: Preclinical
Molecular Formula: C44H58N6O14
Molecular Weight: 894.98
Molecule Type: Protein
Associated Items:
ID: ALA159723
Max Phase: Preclinical
Molecular Formula: C44H58N6O14
Molecular Weight: 894.98
Molecule Type: Protein
Associated Items:
Canonical SMILES: CC[C@H](NC(=O)[C@H](CC1CCCCC1)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(=O)O)NC(C)=O)C(c1ccccc1)c1ccccc1)C(=O)O
Standard InChI: InChI=1S/C44H58N6O14/c1-3-29(44(63)64)46-41(60)32(23-26-13-7-4-8-14-26)49-39(58)30(19-21-34(52)53)48-43(62)38(37(27-15-9-5-10-16-27)28-17-11-6-12-18-28)50-40(59)31(20-22-35(54)55)47-42(61)33(24-36(56)57)45-25(2)51/h5-6,9-12,15-18,26,29-33,37-38H,3-4,7-8,13-14,19-24H2,1-2H3,(H,45,51)(H,46,60)(H,47,61)(H,48,62)(H,49,58)(H,50,59)(H,52,53)(H,54,55)(H,56,57)(H,63,64)/t29-,30-,31-,32-,33-,38-/m0/s1
Standard InChI Key: HCCZVIPVSOHWHY-PRSJUXBDSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Protein | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 894.98 | Molecular Weight (Monoisotopic): 894.4011 | AlogP: 1.42 | #Rotatable Bonds: 26 |
Polar Surface Area: 323.80 | Molecular Species: ACID | HBA: 10 | HBD: 10 |
#RO5 Violations: 2 | HBA (Lipinski): 20 | HBD (Lipinski): 10 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 3.25 | CX Basic pKa: | CX LogP: 1.01 | CX LogD: -11.84 |
Aromatic Rings: 2 | Heavy Atoms: 64 | QED Weighted: 0.06 | Np Likeness Score: 0.18 |
1. Narjes F, Koehler KF, Koch U, Gerlach B, Colarusso S, Steinkühler C, Brunetti M, Altamura S, De Francesco R, Matassa VG.. (2002) A designed P1 cysteine mimetic for covalent and non-covalent inhibitors of HCV NS3 protease., 12 (4): [PMID:11844705] [10.1016/s0960-894x(01)00842-3] |
2. Meanwell NA.. (2011) Synopsis of some recent tactical application of bioisosteres in drug design., 54 (8): [PMID:21413808] [10.1021/jm1013693] |
3. Meanwell NA.. (2018) Fluorine and Fluorinated Motifs in the Design and Application of Bioisosteres for Drug Design., 61 (14): [PMID:29400967] [10.1021/acs.jmedchem.7b01788] |
4. Mei H, Han J, Klika KD, Izawa K, Sato T, Meanwell NA, Soloshonok VA.. (2020) Applications of fluorine-containing amino acids for drug design., 186 [PMID:31740056] [10.1016/j.ejmech.2019.111826] |
5. Meanwell NA.. (2016) 2015 Philip S. Portoghese Medicinal Chemistry Lectureship. Curing Hepatitis C Virus Infection with Direct-Acting Antiviral Agents: The Arc of a Medicinal Chemistry Triumph., 59 (16): [PMID:27501244] [10.1021/acs.jmedchem.6b00915] |
Source(1):